“And then the guidance that we've given, you know, implies both the top and bottom line acceleration in Q4, even though we still have this distributor issue in Q4.”

In context

“. So we have confidence in this because the progress, you know, we feel we have confidence in this because of progress we're making and how we're holding in other parts of the business. Mike, anything you want to add to that? Mike Marinaro: I think you've outlined it really well, Geoff. We are focused on our areas of growth that you highlighted, where we can gain share. This dynamic that we experienced this quarter was a bit unique, and it did come in late, although we have had conversations, we understand what the objectives are, we expect that when we hit those levels that we then see more normalized performance moving forward. So that really should address that issue and then we get it back into our normal sort of rhythm focusing on the areas of growth that you described? Geoff Martha: And then the guidance that we've given, you know, implies both the top and bottom line acceleration in Q4, even though we still have this distributor issue in Q4. And this is driven largely by, you know, acceleration of CV, because, you know, cardiovascular will accelerate and drive upside going forward. So when you think about cardiovascular, we've had about 10 quarters in a row of mid-single-digit growth without much of any contribution from CAS or Ardian. And, let's refer to this as like the CV based business, you know, without CAS and Ardian. And we'll continue to see this performance in the base business driven by above market performance in CRM, think leadless, conduction system pacing, EBICD. And, again, as I mentioned, the commentary structural heart's in a great place and with strong evidence and that we'll keep building upon and product improvements that have come out and Evolut FX plus and, you know, I think just better commercial execut”